Literature DB >> 18534918

Nonmedical costs of colorectal cancer screening with the fecal occult blood test and colonoscopy.

Steven J Heitman1, Flora Au, Braden J Manns, S Elizabeth McGregor, Robert J Hilsden.   

Abstract

BACKGROUND & AIMS: The nonmedical costs of colorectal cancer screening are unknown. However, they might influence screening uptake and impact the cost-effectiveness of colorectal cancer screening modalities.
METHODS: Consecutive individuals presenting for colorectal cancer screening in the Calgary Health Region were recruited from 4 community laboratory collection sites (fecal occult blood test) and 2 endoscopy units (colonoscopy). Subjects completed a questionnaire including items on time off work for the subject and any accompanying caregiver, travel details, and direct out-of-pocket expenses (bowel prep). Time costs were valued at Government of Canada wage rates. Travel costs included estimated costs for travel by car and actual parking costs and taxi and public transportation fares. Car users' costs were calculated by using a Canadian Automobile Association estimate of motoring costs per kilometer. Costs are in 2006 Canadian dollars.
RESULTS: The final sample included 604 subjects who underwent fecal occult blood test (mean age, 62 years; 51% male; 43% employed) and 723 who underwent colonoscopy (mean age, 56; 49% male; 66% employed). Eighty percent of colonoscopy subjects required an accompanying caregiver, compared with only 5% for fecal occult blood test. The nonmedical costs (subject +/- caregiver) averaged $308 for colonoscopy and $36 for fecal occult blood test.
CONCLUSIONS: The nonmedical costs of colorectal cancer screening are substantial, especially for colonoscopy. However, the costs are similar with repeated fecal occult blood tests. These costs might be one factor accounting for low colorectal cancer screening uptake rates. Nonmedical costs should be incorporated into economic analyses of colorectal cancer screening.

Entities:  

Mesh:

Year:  2008        PMID: 18534918     DOI: 10.1016/j.cgh.2008.03.006

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  7 in total

1.  Prospective assessment of out-of-pocket patient-related cost for ERCP at an urban tertiary care medical center.

Authors:  C Mel Wilcox; Roshan Patel; Chad Burski; Shyam Varadarajulu; Meredith Kilgore
Journal:  Dig Dis Sci       Date:  2011-08-05       Impact factor: 3.199

2.  Patients and caregivers costs for colonoscopy-based colorectal cancer screening: Experience of low-income individuals undergoing free colonoscopies.

Authors:  Sonja Hoover; Sujha Subramanian; Florence K L Tangka; Maggie Cole-Beebe; Amy Sun; Cheryl L Kramer; Gina Pacillio
Journal:  Eval Program Plann       Date:  2017-01-07

3.  Unsedated peroral wireless pH capsule placement vs. standard pH testing: a randomized study and cost analysis.

Authors:  Christopher N Andrews; Daniel C Sadowski; Adriana Lazarescu; Chad Williams; Emil Neshev; Martin Storr; Flora Au; Steven J Heitman
Journal:  BMC Gastroenterol       Date:  2012-05-31       Impact factor: 3.067

4.  Colorectal cancer screening for average-risk North Americans: an economic evaluation.

Authors:  Steven J Heitman; Robert J Hilsden; Flora Au; Scot Dowden; Braden J Manns
Journal:  PLoS Med       Date:  2010-11-23       Impact factor: 11.069

Review 5.  Colorectal Cancer Screening and Surveillance for Non-Hereditary High-Risk Groups-Is It Time for a Re-Think?

Authors:  James S Hampton; Linda Sharp; Dawn Craig; Colin J Rees
Journal:  Curr Treat Options Gastroenterol       Date:  2021-01-05

6.  Economic Pressure and Intention to Complete Colorectal Cancer Screening: A Cross-Sectional Analysis Among U.S. Men.

Authors:  Kevin M Korous; Deeonna E Farr; Ellen Brooks; Fa Tuuhetaufa; Charles R Rogers
Journal:  Am J Mens Health       Date:  2022 Sep-Oct

7.  Empirical evidence of the continuing improvement in cost efficiency of an endoscopic surveillance programme for gastric cancer in Singapore from 2004 to 2010.

Authors:  Hui Jun Zhou; Shu Chuen Li; Nasheen Naidoo; Feng Zhu; Khay Guan Yeoh
Journal:  BMC Health Serv Res       Date:  2013-04-15       Impact factor: 2.655

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.